Q3 2024 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
Good morning, ladies and gentlemen. Welcome to the Q3 FY24 earnings conference call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Utkarsh Gandhi, General Manager, Investor Relations for Glenmark Pharmaceuticals. Thank you, and over to you, sir.
Thank you, Lizanne. Good morning, everyone. Welcome to the Q3 FY24 results conference call of Glenmark Pharmaceuticals Limited. Before we start the Q&A, we'll review the overall performance of the company for the third quarter of FY24.
For third quarter of FY24, Glenmark's consolidated revenue from operations was at INR29,096 million as against INR34,639 million in the corresponding quarter last year, recording a YoY decline of 16%. The lower sales in the current quarter was mainly on account of a one-time impact on the company's India business.
And excluding this impact, the approximate growth over previous year
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |